Publication:
Development Refractoriness of MLL-Rearranged Human B Cell Acute Leukemias to Reprogramming into Pluripotency

dc.contributor.authorMuñoz-López, Alvaro
dc.contributor.authorRomero-Moya, Damià
dc.contributor.authorPrieto, Cristina
dc.contributor.authorRamos-Mejía, Verónica
dc.contributor.authorAgraz-Doblas, Antonio
dc.contributor.authorVarela, Ignacio
dc.contributor.authorBuschbeck, Marcus
dc.contributor.authorPalau, Anna
dc.contributor.authorCarvajal-Vergara, Xonia
dc.contributor.authorGiorgetti, Alessandra
dc.contributor.authorFord, Anthony
dc.contributor.authorLako, Majlinda
dc.contributor.authorGranada, Isabel
dc.contributor.authorRuiz-Xivillé, Neus
dc.contributor.authorRodriguez Perales, Sandra
dc.contributor.authorTorres-Ruiz Raul, Raul
dc.contributor.authorStam, Ronald W
dc.contributor.authorFuster, Jose Luis
dc.contributor.authorFraga, Mario F
dc.contributor.authorNakanishi, Mahito
dc.contributor.authorCazzaniga, Gianni
dc.contributor.authorBardini, Michela
dc.contributor.authorCobo, Isabel
dc.contributor.authorBayon, Gustavo F
dc.contributor.authorFernandez, Agustín F
dc.contributor.authorBueno, Clara
dc.contributor.authorMenéndez, Pablo
dc.contributor.funderUnión Europea. Comisión Europea. European Research Council (ERC)
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderMinisterio de Economía y Competitividad (España)
dc.contributor.funderAsociación Española Contra el Cáncer
dc.contributor.funderMinisterio de Ciencia e Innovación (España)
dc.contributor.funderFundación La Caixa
dc.contributor.funderFundación Josep Carreras Contra la Leucemia
dc.contributor.funderGovernment of Catalonia (España)
dc.contributor.funderInstitució Catalana de Recerca i Estudis Avançats
dc.contributor.funderBiotechnology and Biological Sciences Research Council (Reino Unido)
dc.contributor.funderMedical Research Council (Reino Unido)
dc.date.accessioned2019-10-30T10:04:21Z
dc.date.available2019-10-30T10:04:21Z
dc.date.issued2016-10-11
dc.description.abstractInduced pluripotent stem cells (iPSCs) are a powerful tool for disease modeling. They are routinely generated from healthy donors and patients from multiple cell types at different developmental stages. However, reprogramming leukemias is an extremely inefficient process. Few studies generated iPSCs from primary chronic myeloid leukemias, but iPSC generation from acute myeloid or lymphoid leukemias (ALL) has not been achieved. We attempted to generate iPSCs from different subtypes of B-ALL to address the developmental impact of leukemic fusion genes. OKSM(L)-expressing mono/polycistronic-, retroviral/lentiviral/episomal-, and Sendai virus vector-based reprogramming strategies failed to render iPSCs in vitro and in vivo. Addition of transcriptomic-epigenetic reprogramming "boosters" also failed to generate iPSCs from B cell blasts and B-ALL lines, and when iPSCs emerged they lacked leukemic fusion genes, demonstrating non-leukemic myeloid origin. Conversely, MLL-AF4-overexpressing hematopoietic stem cells/B progenitors were successfully reprogrammed, indicating that B cell origin and leukemic fusion gene were not reprogramming barriers. Global transcriptome/DNA methylome profiling suggested a developmental/differentiation refractoriness of MLL-rearranged B-ALL to reprogramming into pluripotency.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipThis work was supported by the European Research Council to P.M. (ERC-2014-CoG-646903), the ISCIII/FEDER (E-Rare-2 Call PI12/03112 to P.M. and PI14/01191 to C.B.), MINECO (SAF2013-43065 to P.M.), and the Spanish Association Against Cancer (AECC) to P.M. and C.B. C.B. is supported by a Miguel Servet II contract (CPII13/00011). D.R.M. and A.M.-L. are supported by PFIS (FI11/0511) and FPI (BES-2014-067844) scholarships, respectively. P.M. also acknowledges financial support from the Obra Social La Caixa, Fundacio Josep Carreras and The Generalitat de Catalunya (SGR330). C.B. and P.M. are investigators of TERCEL.es_ES
dc.format.number4es_ES
dc.format.page602-618es_ES
dc.format.volume7es_ES
dc.identifier.citationStem Cell Reports. 2016;7(4):602-618.es_ES
dc.identifier.doi10.1016/j.stemcr.2016.08.013es_ES
dc.identifier.e-issn2213-6711es_ES
dc.identifier.issn22136711es_ES
dc.identifier.journalStem cell reportses_ES
dc.identifier.pubmedID27666791es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/8534
dc.language.isoenges_ES
dc.publisherCell Press
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/PI14/01191es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/PI12/03112es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/SAF2013-43065es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/CPII13/00011es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/FI11/0511es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/BES-2014-067844es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/EC/H2020/646903es_ES
dc.relation.publisherversionhttps://doi.org/10.1016/j.stemcr.2016.08.013.es_ES
dc.repisalud.institucionCNIOes_ES
dc.repisalud.orgCNIOCNIO::Unidades técnicas::Unidad de Citogenética Moleculares_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectB-ALLes_ES
dc.subjectDNA methylomees_ES
dc.subjectMLL-AF4es_ES
dc.subjectSendai viruses_ES
dc.subjectCancer reprogramminges_ES
dc.subjectiPSCes_ES
dc.subjectTranscriptomees_ES
dc.subject.meshAnimalses_ES
dc.subject.meshBiomarkerses_ES
dc.subject.meshCell Line, Transformedes_ES
dc.subject.meshCell Line, Tumores_ES
dc.subject.meshCell Transdifferentiationes_ES
dc.subject.meshCluster Analysises_ES
dc.subject.meshDNA Methylationes_ES
dc.subject.meshGene Expressiones_ES
dc.subject.meshGene Expression Profilinges_ES
dc.subject.meshHematopoietic Stem Cellses_ES
dc.subject.meshHeterograftses_ES
dc.subject.meshHumanses_ES
dc.subject.meshInduced Pluripotent Stem Cellses_ES
dc.subject.meshMicees_ES
dc.subject.meshMyeloid Progenitor Cellses_ES
dc.subject.meshMyeloid-Lymphoid Leukemia Proteines_ES
dc.subject.meshOncogene Proteins, Fusiones_ES
dc.subject.meshPhenotypees_ES
dc.subject.meshPrecursor B-Cell Lymphoblastic Leukemia-Lymphomaes_ES
dc.subject.meshPrecursor Cells, B-Lymphoides_ES
dc.subject.meshTranscriptomees_ES
dc.subject.meshTranslocation, Genetices_ES
dc.subject.meshCellular Reprogramminges_ES
dc.subject.meshGene Rearrangementes_ES
dc.titleDevelopment Refractoriness of MLL-Rearranged Human B Cell Acute Leukemias to Reprogramming into Pluripotencyes_ES
dc.typejournal articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublicationcac6c6e2-06a9-4548-b216-3d7d32ed6b6e
relation.isAuthorOfPublication.latestForDiscoverycac6c6e2-06a9-4548-b216-3d7d32ed6b6e
relation.isFunderOfPublicationcb2ee04a-8d42-4a64-b3f6-3c156f222b35
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublication77b2fc20-6311-4e46-98a7-83e46257b93b
relation.isFunderOfPublication453a1189-9bca-4be8-8d60-695f50fe028b
relation.isFunderOfPublication289dce42-6a28-4892-b0a8-c70c46cbb185
relation.isFunderOfPublicationf04d23ec-a91d-4242-88b0-cc436888f8a2
relation.isFunderOfPublicationeb3dfac0-f6ee-4d98-8827-ff967033876c
relation.isFunderOfPublicationc6fbffec-abb4-4f0e-81e0-3b254d5dd85d
relation.isFunderOfPublication597d8a00-f8e8-45dd-b797-5ecfd2271de6
relation.isFunderOfPublicatione7c5d7e0-62e6-43f3-8157-4eef3c92d459
relation.isFunderOfPublication0a2c122a-0ea9-4e9e-a57a-35e632489fa3
relation.isFunderOfPublication.latestForDiscoverycb2ee04a-8d42-4a64-b3f6-3c156f222b35
relation.isPublisherOfPublicationaea619d1-42a6-47f8-84e2-6bc27d6f8300
relation.isPublisherOfPublication.latestForDiscoveryaea619d1-42a6-47f8-84e2-6bc27d6f8300

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
DevelopmentRefractorinessofMLL-Rearranged_2016.pdf
Size:
3.42 MB
Format:
Adobe Portable Document Format
Description:
Loading...
Thumbnail Image
Name:
DevelopmentRefractorinessofMLL-Rearranged-mmc1.pdf
Size:
8 MB
Format:
Adobe Portable Document Format
Description: